We report the experience with 2,000 consecutive patients with advanced cancer who underwent testing on a genomic testing protocol, including the frequency of actionable alterations across tumor types, subsequent enrollment onto clinical trials, and the challenges for trial enrollment.
INTRODUCTION
The increasing availability of next-generation sequencing combined with the availability of molecular therapeutics targeting genomically defined populations has created a growing interest in using multiplexed genomic profiling for routine cancer care and, in particular, for directing patients to relevant clinical trials. However, implementation of genomically informed therapy requires not only access to genomic profiling, but also the availability of molecularly targeted therapies matched to the genomic testing results. Availability of clinical trials may not only differ from institution to institution, but may also differ between tumor types. Enrollment onto clinical trials is also limited by trial eligibility criteria, as well as availability of slots.
As a result of growing physician and patient demand for genomic profiling at The University of Texas MD Anderson Cancer Center, we initiated a prospective clinical study where physicians were able to enroll patients who they felt would benefit from multiplex genomic testing and where patients were likely to consider enrollment onto therapeutic clinical trials. Patients with any malignancy were eligible for the study and underwent genomic testing on a Clinical Laboratory Improvement Amendments (CLIA) -compliant platform after informed consent. Here, we report the experience with the first 2,000 patients who underwent testing on the genomic testing protocol, including the
Genomic Analysis
Samples were evaluated using hematoxylin and eosin staining for tumor cellularity. DNA was extracted, purified, and quantified. Genomic analysis was performed by mass spectroscopy-based multiplex assay to assess the mutational status of hotspot regions in 11 genes (first 251 patients) or with nextgeneration sequencing using the Ion Ampliseq Cancer Panel (Life Technologies, Grand Island, NY) to assess hotspot mutations in 46 genes (Appendix Table A1 , online only). In the last few months, testing expanded to 50 genes by adding EZH2, IDH2, GNA11, and GNAQ (33 patients, Appendix Table A1 ).
Sequence alignment and base calling were performed by Torrent Suite software V2.0.1 (Life Technologies) with Human Genome Build 19 (Hg19) as reference. Torrent Variant Caller software V1.0 (Life Technologies) was used for variant detection, and the Integrative Genomics Viewer (http://www.broadinstitute.org/igv/) was used to visualize variants. OncoSeek software was used to integrate the data. 1 Routine germline testing was not performed. Germline variants were defined based on relative prevalence within the MD Anderson Cancer Center patient population and by comparing the data with dbSNP v.138 (http://www.ncbi.nlm.nih.gov/projects/SNP/) global minor allele frequency numbers where available, as previously described. 2 Variants classified as likely to be germline are listed in Appendix Table  A2 (online only).
Analysis
Alterations potentially targetable with established or investigational therapeutics directly or indirectly (eg, inhibiting downstream signaling) were considered actionable. The actionable genes are designated by asterisks in Appendix Table A1 . The therapeutic implications of potentially actionable genes are listed in Appendix Table A3 (online only) .
Categorical variables were summarized in frequency tables. Mutation rates were calculated based on the tested samples. The association between the presence or absence of actionable mutations and enrollment onto a clinical trial after the genomic testing was assessed using a Pearson 2 test. Figure 1A . The most frequently mutated genes (with likely somatic mutations) are shown in Figure 1B .
RESULTS

From
Of the 2,000 patients, 789 (39%) had at least one mutation in a potentially actionable gene, 414 (21%) had a presumed somatic mutation in a gene that was not actionable, 205 (10%) had a likely germline variant, and 592 (30%) had no mutations/variants identified (Fig 2A) . Notably, most alterations considered as likely germline noted on this panel were not known functional polymorphisms or pathogenic germline mutations and were not considered actionable. One hundred forty-five patients (7.3%) had two or more potentially actionable alterations. It should be noted that for this analysis, we considered TP53, IDH1, and IDH2 mutations not actionable because of lack of genotype-matched trials for solid tumors during that time period, and we considered KRAS actionable because of availability of trials targeting MEK1, with or without KRAS selection. If KRAS was also considered not actionable, 627 patients (31%) had a mutation in a potentially actionable gene (Fig 2B) . If TP53, IDH1, and IDH2 were considered potentially actionable, 1,156 patients (58%) had a mutation in a potentially actionable gene (Fig 2C) . For the likely somatic mutations identified, only six genes were present at greater than 5% (with not all of these being druggable), six genes were present at a frequency of between 1% and 5%, and the remainder were present at less than 1% (Fig 1) . On the basis of the mutation spectrum assessed, the percentage of patients with potentially actionable alterations varied from 5% to 79% by tumor type (Figs 2A to 2C ). As we transitioned from the 11-gene Sequenom panel to the 46-and 50-gene Ampliseq panels, there were only modest increases in patients with potentially actionable alterations (Data Supplement).
The frequency of mutations in specific genes is shown for different tumor types where 20 patients or more were tested (Table 1) . In addition to the expected common disease-mutation associations (eg, KRAS-colon cancer, EGFR-lung cancer), we identified a set of potentially actionable genes frequently mutated in specific diseases but also uncommonly mutated in other cancer types (eg, BRAF, PIK3CA). Furthermore, some genes had a low incidence of mutations across several tumor types (eg, ERBB2; Fig 3) .
Enrollment Onto Clinical Trials
Five hundred nineteen patients (26%) enrolled onto therapeutic clinical trials at MD Anderson Cancer Center after genomic testing results were available (Fig 4A) . Patients with mutations in potentially actionable genes were marginally more likely to be treated on therapeutic clinical trials after test results were available than those without actionable mutations (28.4% v 24.4%, respectively; P ϭ .0445; Fig 4B) .
Among the 789 patients with potentially actionable alterations (defined as shown in Fig 2A) , 83 (11%) went on genotype-matched trials after genomic testing; 54 (7%) were treated on a genotypeselected trial (requiring a mutation for eligibility), and 29 (4%) were treated on a genotype-relevant trial (ie, a trial without biomarker selection but with an agent that targeted the gene product or downstream signaling). In addition, 121 patients (15%) were treated on other clinical trials (Fig 3C) . Figure 4D demonstrates the key genomic alterations of patients who were enrolled onto genotype-matched trials. The right panel in Figure 4D depicts the key genomic alterations of patients who were enrolled onto genotype-matched trials excluding 24 patients who had alterations detectable by standardof-care assays (EGFR in lung cancer, BRAF in melanoma, and KRAS in colon cancer).
To gain insights into obstacles for trial enrollment, we reviewed the records of the 429 patients with PIK3CA/AKT1/PTEN/BRAF mutations. The median time from CLIA test results to last follow-up was 257 days (range, 4 to 749 days for patients who returned to clinic). Surprisingly, 199 (46%) of 429 patients with PIK3CA/AKT1/PTEN/ BRAF mutations did not undergo a new regimen of therapy at our institution after testing ( Fig 5A) ; 75 (17%) of 429 patients did not return to the institution after testing, 55 (13%) returned but elected to be treated elsewhere (usually locally; ie, closer to home), 26 (6%) did not initiate new treatment as a result of declining performance status, and 43 (10%) did not start new treatment for other reasons (eg, stable disease). Of the 230 patients who received a new treatment at MD Anderson Cancer Center, 40 (17%) were treated on genotype-selected trials after testing, 16 (7%) were treated on genotype-relevant trials, 35 (15%) were treated on other trials, and 40 (17%) received a genotyperelevant drug (as standard of practice or off protocol) after testing ( Fig  5B) . In addition, eight patients (2%) had been treated on a genotyperelevant trial before testing, and 12 patients (5%) received a genotyperelevant drug off protocol before testing. Thus, of the 230 patients with PIK3CA/AKT1/PTEN/RAF mutations who received subsequent therapy at MD Anderson Cancer Center, 116 (50%) received a genotypematched drug (96 patients after testing, 42%).
The clinical course of the 429 patients with PIK3CA/AKT/PTEN/ BRAF mutations is shown in Figure 5C . Of the 354 patients who returned to the institution after testing, 230 went on to subsequent new regimens. One hundred fifty-eight (68%) of 230 patients had the genomic testing result noted in the transcribed clinical notes, 106 (46%) had documentation of discussion of genotype-matched trials, and 61 (27%) were enrolled onto a genotype-matched trial (Fig 5C) . Trials were discussed with 45 patients who subsequently were not treated on a genotype-matched trial but rather elected noninvestigational therapy, a non-genotype-matched trial, or treatment elsewhere or received genotype-relevant drug off protocol. In addition, slots could not be identified for four patients, four patients had too poor performance status, 11 patients were ineligible for trials for other reasons, and one patient had insurance denial for trial participation.
Also of note, 13 patients ultimately went on more than one genotype-matched trial after genomic testing. Fourteen patients had more than one actionable genomic alteration, and two patients went on trials simultaneously targeting two alterations (one patient with KRAS and PIK3CA and the other with KIT and PIK3CA).
We also evaluated the time required for genomic testing. and median of 26 days. Notably, 102 patients (23.8%) with PIK3CA/ AKT1/PTEN/BRAF mutations had another treatment started before test results were received; 13 of these were genotype-relevant choices.
DISCUSSION
Broad implementation of multiplex hotspot testing across an institution is feasible. However, overall, only a small portion of patients with actionable alterations were enrolled onto genotype-matched trials. Notably, 46% of patients with PIK3CA, AKT, PTEN, or BRAF alterations did not receive subsequent treatment at the institution; however, of patients who received subsequent treatment, 23% were treated on a genotype-matched trial after genomic testing. One hundred fifteen (48%) of 242 patients who received additional treatment after multiplex testing received a genotyperelevant drug. Thus, for patients who receive additional treatment, NOTE. Two thousand patient underwent testing overall, 1,749 patients on Ion Torrent platform and 251 patients on Sequenom platform. Thirty-three patients underwent EZH2 and GNA11 mutation testing and 352 had GNAQ testing, and no mutations were found. In addition, 352 patients had IDH2 testing, and two mutations were found (in brain tumors). Abbreviation: CRC, colorectal cancer.
multiplex testing was used to drive genomically informed clinical decision making. Seven hundred eighty-nine patients (39%) had a mutation in a potentially actionable gene. However, the frequency of actionable alterations differs widely (from 5% to 79%) between different tumor lineages; thus, the utility of this platform may differ based on tumor type. Furthermore, likely actionable mutations at a frequency of greater than 5% were present in only four genes, and likely actionable 
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www.jco.org mutations at a frequency between 1% and 5% were also present in only four genes. The low frequency of mutations in most actionable genes could present a challenge for validating the actionability of the targets. In addition, to identify sufficient patients for genotypeselected trials, it will be necessary to test large numbers of patients with multiplexed testing.
For this analysis, we categorized TP53, IDH1, and IDH2 as not actionable, although IDH-targeted therapies are now in trials, and recently trials have started using TP53 as a selection marker. Also notable is that we considered KRAS as an actionable gene, because there are KRAS genotype-selected trials. However, these trials may not be applicable for several tumor types, and available slots are limited; thus, this is an overestimation of true actionability. Although we categorized mutations as being in a potentially actionable gene, it should be noted that during clinical trial consideration, the level of evidence for the functional impact of each mutation also needs to be considered. Therefore, the frequency of actionable mutations may be less than the frequency of mutations in potentially actionable genes. Also of note, there is growing interest in using larger panels, such as whole-exome sequencing or targeted full-length sequencing of actionable genes. These approaches not only cover nonhotspot alterations, but they may also yield copy number information and, depending on design, gene rearrangements. Such larger panels may demonstrate potentially actionable alterations in many more patients. [3] [4] [5] [6] We noted several challenges in linking genomic testing to genomically matched trials. First, 17% of patients did not return to MD Anderson Cancer Center after testing, and 13% elected to be treated closer to home. Therefore, in nearly a third of the patients, the genomic information from testing was likely not used for therapy planning. This is at least in part attributable to MD Anderson Cancer Center being a referral center. Although one option would be to limit testing to patients who are local, genomic testing remains an important tool to deliver the most informative consultations. However, before testing, it is important to determine whether the patient is interested in clinical trials. Second, 6% of patients did not initiate new treatment as a result of declining performance status, and several were ineligible for trials because of their performance status. It remains difficult to predict health deterioration in patients with advanced 28. 4 24.4
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Genotype-matched trial after genomic testing? cancer, and unfortunately, 105 patients (5%) died within 3 months of testing. Thus, careful assessment of performance status and comorbidities is needed. Testing for non-standard-of-care markers is most likely to benefit patients with adequate performance status to participate in clinical trials in the next two lines of treatment. Many patients underwent genomic characterization to guide future treatments rather than point-of-care testing to decide on nextline therapy. This approach allows for the most expedited delivery of the next line of therapy but represents an opportunity lost for enrollment onto genotype-matched trials. In our study, time from consent to genomic report was a median of 26 days; this delay, at least in part, is attributable to the time to locate archival tissue blocks. Point-of-care tumor biopsies for molecular profiling or liquid biopsy approaches may not only immediately obtain samples for testing, but may also overcome potential challenges as a result of genomic evolution.
Even studies that have performed point-of-care testing have demonstrated the challenges to offering a genotype-matched treatment option to all patients. In the Lung Cancer Mutation Consortium, an oncogenic driver was found in 64% of patients who underwent genomic testing; however, only 28% of patients were enrolled onto a marker-selected trial. 7 In the SAFIR01 breast cancer trial, a targetable alteration was identified in 46% of patients and therapy was personalized in 13% of patients, with 28% of patients with a targetable alteration receiving a matched therapy. 8 In the institutional series from Vanderbilt, Lovly et al 9 reported that among 150 patients with melanoma who underwent SNaPSHOT testing, 60% had at least one mutation and 43% of patients harboring metastatic disease with actionable mutations were treated in genomically matched trials. In our study, genomic analysis was not point-of-care testing and was not linked to a prespecified treatment algorithm. Keeping that in mind, with widespread implementation of genomic testing, enrollment of 11% of patients who underwent genomic testing onto genomically matched trials overall and nearly 40% of patients with PIK3CA/AKT/ PTEN/BRAF mutations receiving genomically relevant drugs after testing establish the potential value of genomic testing for therapy selection. However, a major obstacle was the paucity of genomically matched trials, especially for less common tumor types and for the less commonly mutated genes. Tracking frequency of alterations (Table 1) can help determine feasibility of genotype-selected trials in each disease type.
Over the study period, there was a steady increase in number of genes for which we have genotype-selected trials. We have leveraged our genomic testing to design genotype-selected investigator-initiated trials. We have also recruited several industry-sponsored trials and activated genomically selected histology-independent basket trials. Novel trial approaches to explore antitumor efficacy in rare molecular subtypes and novel trial access mechanisms such as just-in-time trial access activating genomically matched trials appropriate for individual patient genotype are needed.
Our study was observational in design; we relied on retrospective assessment of impact of testing on treatment choices. Notably, only 69% patients had the genomic testing results acknowledged in the transcribed clinic notes, and 44% had documentation of discussion of genotype-matched trials. It is unclear whether test results were indeed not appreciated and trial options not discussed or whether these were simply not documented. However, it is possible that alerting treating physicians that genomic testing results are available may improve trial accrual. To facilitate this, we have activated a clinical trial alert system. Physicians now receive an e-mail alert when actionable genomic test results are received, with a list of genotype-matched trials. It has been recently reported that even oncologists at leading cancer centers have variable comfort levels with their knowledge of genomics. 10 To assist in decision making, we have put together a Precision Oncology Decision Support Team. For common actionable genes, variant-level information on mutations that have been experimentally characterized based on published literature is included on our Web site PersonalizedCancerTherapy.org. We expect that by increasing education and streamlining decision making, we can improve the implementation of genomically informed cancer therapy. NOTE. Genes were classified as potentially actionable if there is at least preclinical evidence suggesting genomic alteration may affect function and the gene can be targeted with an approved or investigational agent or if the gene is being used as an enrollment criterion for ongoing genotype-selected trials. Abbreviations: AML, acute myeloid leukemia; EGFR, epidermal growth factor receptor; HER4, human epidermal growth factor receptor 4; mTOR, mammalian target of rapamycin; PARP, poly (ADP-ribose) polymerase; PDGFRA, platelet-derived growth factor receptor alpha; PI3K, phosphatidylinositol 3-kinase.
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